These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 21388992)

  • 1. Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study.
    Metra M; O'Connor CM; Davison BA; Cleland JG; Ponikowski P; Teerlink JR; Voors AA; Givertz MM; Mansoor GA; Bloomfield DM; Jia G; DeLucca P; Massie B; Dittrich H; Cotter G
    Eur Heart J; 2011 Jun; 32(12):1519-34. PubMed ID: 21388992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment.
    Cotter G; Dittrich HC; Weatherley BD; Bloomfield DM; O'Connor CM; Metra M; Massie BM;
    J Card Fail; 2008 Oct; 14(8):631-40. PubMed ID: 18926433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure.
    Massie BM; O'Connor CM; Metra M; Ponikowski P; Teerlink JR; Cotter G; Weatherley BD; Cleland JG; Givertz MM; Voors A; DeLucca P; Mansoor GA; Salerno CM; Bloomfield DM; Dittrich HC;
    N Engl J Med; 2010 Oct; 363(15):1419-28. PubMed ID: 20925544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function.
    Weatherley BD; Cotter G; Dittrich HC; DeLucca P; Mansoor GA; Bloomfield DM; Ponikowski P; O'Connor CM; Metra M; Massie BM;
    J Card Fail; 2010 Jan; 16(1):25-35. PubMed ID: 20123315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function).
    Voors AA; Dittrich HC; Massie BM; DeLucca P; Mansoor GA; Metra M; Cotter G; Weatherley BD; Ponikowski P; Teerlink JR; Cleland JG; O'Connor CM; Givertz MM
    J Am Coll Cardiol; 2011 May; 57(19):1899-907. PubMed ID: 21545947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial.
    Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Ponikowski P; Unemori E; Voors AA; Adams KF; Dorobantu MI; Grinfeld LR; Jondeau G; Marmor A; Masip J; Pang PS; Werdan K; Teichman SL; Trapani A; Bush CA; Saini R; Schumacher C; Severin TM; Metra M;
    Lancet; 2013 Jan; 381(9860):29-39. PubMed ID: 23141816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physician-determined worsening heart failure: a novel definition for early worsening heart failure in patients hospitalized for acute heart failure--association with signs and symptoms, hospitalization duration, and 60-day outcomes.
    Cotter G; Metra M; Weatherley BD; Dittrich HC; Massie BM; Ponikowski P; Bloomfield DM; O'Connor CM
    Cardiology; 2010; 115(1):29-36. PubMed ID: 19844102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance.
    Givertz MM; Massie BM; Fields TK; Pearson LL; Dittrich HC;
    J Am Coll Cardiol; 2007 Oct; 50(16):1551-60. PubMed ID: 17936154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk-based evaluation of efficacy of rolofylline in patients hospitalized with acute heart failure - Post-hoc analysis of the PROTECT trial.
    Demissei BG; Postmus D; Liu LCY; Cleland JG; O'Connor CM; Metra M; Ponikowski P; Teerlink JR; Cotter G; Davison BA; Edwards C; Givertz MM; Bloomfield DM; Dittrich HC; Voors AA; Hillege HL
    Int J Cardiol; 2016 Nov; 223():967-975. PubMed ID: 27589047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of serial troponin release on outcomes in patients with acute heart failure: analysis from the PROTECT pilot study.
    O'Connor CM; Fiuzat M; Lombardi C; Fujita K; Jia G; Davison BA; Cleland J; Bloomfield D; Dittrich HC; Delucca P; Givertz MM; Mansoor G; Ponikowski P; Teerlink JR; Voors AA; Massie BM; Cotter G; Metra M
    Circ Heart Fail; 2011 Nov; 4(6):724-32. PubMed ID: 21900185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study.
    Mebazaa A; Pang PS; Tavares M; Collins SP; Storrow AB; Laribi S; Andre S; Mark Courtney D; Hasa J; Spinar J; Masip J; Frank Peacock W; Sliwa K; Gayat E; Filippatos G; Cleland JG; Gheorghiade M
    Eur Heart J; 2010 Apr; 31(7):832-41. PubMed ID: 19906690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes.
    Metra M; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Ponikowski P; Unemori E; Voors AA; Adams KF; Dorobantu MI; Grinfeld L; Jondeau G; Marmor A; Masip J; Pang PS; Werdan K; Prescott MF; Edwards C; Teichman SL; Trapani A; Bush CA; Saini R; Schumacher C; Severin T; Teerlink JR;
    J Am Coll Cardiol; 2013 Jan; 61(2):196-206. PubMed ID: 23273292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT.
    Teerlink JR; Iragui VJ; Mohr JP; Carson PE; Hauptman PJ; Lovett DH; Miller AB; Piña IL; Thomson S; Varosy PD; Zile MR; Cleland JG; Givertz MM; Metra M; Ponikowski P; Voors AA; Davison BA; Cotter G; Wolko D; Delucca P; Salerno CM; Mansoor GA; Dittrich H; O'Connor CM; Massie BM
    Drug Saf; 2012 Mar; 35(3):233-44. PubMed ID: 22339573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of postdischarge outcomes from information acquired shortly after admission for acute heart failure: a report from the Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PROTECT) Study.
    Cleland JG; Chiswell K; Teerlink JR; Stevens S; Fiuzat M; Givertz MM; Davison BA; Mansoor GA; Ponikowski P; Voors AA; Cotter G; Metra M; Massie BM; O'Connor CM
    Circ Heart Fail; 2014 Jan; 7(1):76-87. PubMed ID: 24281134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of the RELAXin in acute heart failure study.
    Ponikowski P; Metra M; Teerlink JR; Unemori E; Felker GM; Voors AA; Filippatos G; Greenberg B; Teichman SL; Severin T; Mueller-Velten G; Cotter G; Davison BA
    Am Heart J; 2012 Feb; 163(2):149-55.e1. PubMed ID: 22305830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single supratherapeutic dose of rolofylline does not prolong the QTcF interval in healthy volunteers.
    Radziszewski W; Lai E; Lazarus Shipitofsky N; Stroh M; Dishy V; Han L; Lewis W; Johnson-Levonas AO; Lutz R; Wagner J
    Am J Ther; 2010; 17(1):8-16. PubMed ID: 20027105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Worsening Heart Failure Following Admission for Acute Heart Failure: A Pooled Analysis of the PROTECT and RELAX-AHF Studies.
    Davison BA; Metra M; Cotter G; Massie BM; Cleland JGF; Dittrich HC; Edwards C; Filippatos G; Givertz MM; Greenberg B; Ponikowski P; Voors AA; O'Connor CM; Teerlink JR;
    JACC Heart Fail; 2015 May; 3(5):395-403. PubMed ID: 25951761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment.
    Dittrich HC; Gupta DK; Hack TC; Dowling T; Callahan J; Thomson S
    J Card Fail; 2007 Oct; 13(8):609-17. PubMed ID: 17923351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60-day outcomes in the PROTECT pilot study.
    Metra M; Cleland JG; Weatherley BD; Dittrich HC; Givertz MM; Massie BM; O'Connor CM; Ponikowski P; Teerlink JR; Voors AA; Cotter G
    Eur J Heart Fail; 2010 May; 12(5):499-507. PubMed ID: 20228387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study.
    Teerlink JR; Metra M; Felker GM; Ponikowski P; Voors AA; Weatherley BD; Marmor A; Katz A; Grzybowski J; Unemori E; Teichman SL; Cotter G
    Lancet; 2009 Apr; 373(9673):1429-39. PubMed ID: 19329178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.